Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ICU
Intensive care unit
CIM
Critical illness myopathy
MPB
Muscle protein breakdown
MPS
Muscle protein synthesis
CT
Computed tomography
CK
Creatine kinase
N-titin
N-terminal fragments of titin
FMM
Femoral muscle mass
Main text
Intensive care unit (ICU)-acquired weakness is a muscular weakness without other cause after intensive care and consisting of critical illness polyneuropathy and critical illness myopathy (CIM) [1]. Muscle atrophy can occur quite early during critical illness because of increased muscle protein breakdown (MPB) and decreased muscle protein synthesis (MPS) [1]. Although muscle mass can be evaluated using ultrasound [2] and computed tomography (CT) [3], MPS and MPB are difficult to evaluate separately. Muscle biopsy can directly evaluate MPB in CIM directly [4], but it is invasive. Creatine kinase cannot evaluate MPB in CIM [1]. Therefore, no noninvasive technique has been established.
Titin, the largest protein expressed specifically in striated muscle, becomes various fragments that are released into blood and urine after muscle damage. Reportedly, the N-terminal fragments of titin (N-titin) excreted in the urine are increased in patients with various muscular diseases [5]. Therefore, N-titin is expected to be a noninvasive biomarker for monitoring MPB and we decided to evaluate the N-titin levels in the acute phase of critically ill patients.
Anzeige
Subjects were four adult patients admitted to our ICU in September 2019. We calculated the correlation coefficient between mean values of N-titin at days 1, 3, 5, and 7 and the femoral muscle mass (FMM) change between days 1 and 10 evaluated with CT. Urine N-titin levels were measured using an enzyme-linked immunosorbent assay kit (#27900 Human Titin N-Fragment Assay Kit, Immuno-Biological Laboratories Co. Ltd., Fujioka, Japan). FMM was calculated using the same method we previously reported [3]. Statistical analysis was done using software: R, ver. 3.6.1.
Subjects were four adults for whom activities of daily living before admission were sufficient for their independent living. Basic characteristics and outcomes of the respective patients are presented in Table 1.
Table 1
Basic characteristics and results for each patient
No.
Age
Sex
Diagnosis
SOFA
APACHEII
Hospital stay
ICU stay
Days on MV until day 10
Total steroids dose until day 10
RRT
Muscle relaxant use
Outcome
BI at day 28
CK (U/L)†
Cre (mg/dL)†
N-titin/Cre (pmol/mgCre/dL)*
FMM change (%)
1
86
F
Bacrerial pneumonia
6
15
20
9
5
PSL 150 mg
–
–
Alive
0
42.3
0.82
42.93
− 28.65
2
48
M
Interstitial pneumonia
6
9
91
15
10
PSL 360 mg
mPSL 4000 mg
–
–
Alive
10
206.4
0.65
42.33
− 19.03
3
86
F
Congestive heart failure
7
20
11
5
2
PSL 180 mg
–
–
Alive
80
72.1
0.82
21.62
− 14.28
4
60
M
Malignant lymphoma
8
11
33
14
9
PSL 160 mg
HYD 1200 mg
–
–
Alive
65
31.7
0.57
29.69
− 20.96
SOFA Sequential Organ Failure Assessment, APACHE II Acute Physiological and Chronic Health Evaluation II, MV mechanical ventilation, RRT renal replacement therapy, BI Barthel Index, CK creatine kinase, N-titin urine titin N-fragment, Cre serum creatinine, FMM femoral muscle mass, PSL prednisolone, mPSL methyl predonisolone, HYD hydrocortisone
*is for N-titin/Cre(pmol/mgCre/dL); †is for CK and Cre
Figure 1 shows N-titin changes of the respective patients. Mean N-titin levels of each patient were 42.93, 42.33, 21.62, and 29.69 (pmol/mgCre). Their respective FMM changes were − 28.65, − 19.03, − 14.28, and − 20.96 (%). The correlation coefficient between the mean value of N-titin level and the FMM change was negative: r = − 0.729. The mean values of creatine kinase for 10 days for the respective patients were 42.3, 206.4, 72.1, and 31.7 (U/L).
Fig. 1
N-titin change of each patient. N-titin values were remarkably high when entering the ICU. They persisted for at least 7 days. N-titin showed continuous increase in patients 1 and 2 and peaked on day 3 in patients 3 and 4
×
The N-titin values of critically ill patients were remarkably high when entering the ICU. They persisted for at least 7 days. The values were negatively correlated with the rate of FMM change. An earlier study [5] revealed that N-titin had a median of 1.2 (pmol/mgCre/dL) at rest in healthy individuals, 27.0 (pmol/mgCre/dL) at the highest after 10 km running, and a median of 735.5 (pmol/mgCre/dL) in patients with Duchenne muscular dystrophy. Although the N-titin levels of these patients were much lower than those of the muscular dystrophy patients, FMM decreased during a short duration. Not prominent but continuous active MPB persisting for a week and reducing MPS from anabolic resistance and malnutrition might have produced these results.
Anzeige
Another previous study [6] showed that N-titin levels in healthy individuals decrease during the first 2 weeks of bed rest. However, the present study showed high values in critically ill patients at ICU admission. These findings suggest that N-titin can reflect the pathological condition of MPB in CIM, which induced much more atrophy than muscle disuse.
No patient in this study was on dialysis. A molecular weight of N-titin is about 26 kDa, and N-titin is not removed by dialysis theoretically. Therefore, N-titin measurements are expected to be effective for patients on dialysis.
In conclusion, N-titin might be useful as a novel biomarker for MPB in CIM. For additional evaluation, a prospective observational study is underway at our hospital (UMIN000038353).
Acknowledgements
We would like to acknowledge all patients involved in this study. We would also like to thank ICU members and radiology technicians for supporting this study.
Ethics approval and consent to participate
N-titin measurements for this study were taken using opt-out recruitment method, as approved by the Ethics Committee of Hitachi General Hospital (2019-37). These four patients were included in another study (UMIN000033783), and consent for CT imaging was already obtained for that study. We obtained written consent from all the patients to use their data for this report. All procedures performed in the study involving human participants were in accordance with the 1964 Declaration of Helsinki and its later amendments or similar ethical standards. Written informed consent from the enrolled patients was waived by the Ethics Committee because the urine samples were obtained after routine laboratory tests.
Consent for publication
Not applicable in this study.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
